Pharmacokinetic Interaction Between HGP0904, HGP0608 and HGP1405
Phase 1
Completed
NCT02387554
| Condition | Hypertension |
|---|
| Phase | Phase 1 |
|---|
| Sponsor | Hanmi Pharmaceutical Company Limited |
|---|
| Status | Completed |
|---|
| Enrollment | 33 participants |
|---|
| Interventions | HGP0904, HGP0608, HGP1405 |
|---|
| Start date | Aug, 2014 |
|---|
| Completion date | Oct, 2014 |
|---|
| Results posted | Jun 12, 2015 |
|---|
Summary
The purpose of this study is to investigate the pharmacokinetic interaction and safety between HGP0904, HGP0608 and HGP1405 when administered alone and in combination in healthy male volunteers
AUClast
0, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 96, 120, 168hr · Ratio(Comb/Alone)
| HGP0904 | 1.0360 Ratio(Comb/Alone) |
|---|
| HGP0608 | 1.1606 Ratio(Comb/Alone) |
|---|
| HGP1405 | 1.0266 Ratio(Comb/Alone) |
|---|
| EXP3174 | 1.0902 Ratio(Comb/Alone) |
|---|
Cmax
0, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 96, 120, 168hr
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.